Biotech startup StrainX Bioworks has raised $13 million in a funding round led by Prime Venture Partners and Leo Capital, the company announced. The round also included investments from Good Startup, Sparrow Capital, Sun Icon Ventures, Dholakia Ventures, and WindT Angels, according to inc42.com. This marks Good Startup’s first investment in an Indian biotech firm.
Founded in 2023 by IIT Delhi alumni Akshay Mittal and Alok Malaviya, StrainX focuses on manufacturing alternative proteins using synthetic biology and precision fermentation. The startup engineers microbes such as bacteria, yeast, and fungal cells to produce proteins derived from non-animal sources. The funds will be used to expand capacity at its bio-manufacturing fermentation facility in Bhopal and to scale commercial production. Additionally, StrainX plans to strengthen its Bengaluru R&D lab by hiring more scientists and enhancing its technological capabilities.
The alternative protein sector is gaining traction globally as demand rises for sustainable food sources and materials. StrainX’s ability to produce these proteins at scale in a lab positions it to compete in markets spanning food, nutrition, materials, and cosmetics. The startup has also secured approval in the US to commercialize its product, underscoring its potential for international expansion.
Looking ahead, StrainX aims to deploy the new capital to accelerate commercial-scale production and expand research efforts. The company’s progress in scaling fermentation processes and synthetic biology applications will be key milestones to watch as it moves toward broader market entry, according to inc42.com.